Medications and Glucose-6-Phosphate Dehydrogenase Deficiency An Evidence-Based Review Ilan Youngster Lidia Arcavi Renata Schechmaster Yulia Akayzen Hen Popliski Janna Shimonov Svetlana Beig Matitiahu Berkovitch Glucose-6-phosphate dehydrogenase (G6PD) deficiency is the most common human enzyme defect and one of the most common genetic disorders worldwide, with an estimated 400 million people worldwide carrying a mutation in the G6PD gene that causes deficiency of the enzyme
Different kinds of pH-cleavable nanocarriers utilizing pH difference between healthy and diseases cell have been reported for the target specific release of active pharmaceutical molecules
The margin of sampling error is plus or minus 3 percentage points for the full sample
Dose proportionality and steady-state pharmacokinetics of serdexmethylphenidate/dexmethylphenidate, a novel prodrug combination to treat attention-deficit/hyperactivity disorder
In different parts from the world different techniques arise that intend to favor the fast determination with high sensitivity and specificity of the activity of this enzyme 55,56
As understanding of growth factor signalling pathways expanded, follistatin variants such as Follistatin-344 began to be studied in experimental cellular models investigating regulatory protein interactions